Dr. Rettig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 UCLA Medical Plz
Ste 140
Los Angeles, CA 90095Phone+1 310-794-7152Fax+1 310-794-1666
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
University of WashingtonResidency, Internal Medicine, 1991 - 1993
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1990 - 1991
Duke University School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1993 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
- Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Start of enrollment: 2014 Sep 23
- Join now to see all
Publications & Presentations
PubMed
- 213 citationsGenomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.David A Quigley, Ha X Dang, Shuang G Zhao, Paul Lloyd, Rahul Aggarwal
Cell. 2018-07-26 - 84 citationsTranscriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J. Alumkal, Duanchen Sun, Eric Lu, Tomasz M. Beer, George Thomas
Proceedings of the National Academy of Sciences of the United States of America. 2020-06-02 - 156 citationsThe DNA methylation landscape of advanced prostate cancerShuang G. Zhao, William S. Chen, Haolong Li, Adam Foye, Meng Zhang
Nature Genetics. 2020-08-01
Journal Articles
- Functional Profiling of Circulating Tumor Cells with an Integrated Vortex Capture and Single-Cell Protease Activity AssaySteven M Dubinett, Matthew B Rettig, Proceedings of the National Academy of Sciences
Press Mentions
Dr. Matthew Rettig Discusses Precision Medicine in Advanced Prostate CancerMay 16th, 2022- Tool Helps Predict Who Will Respond Best to Targeted Prostate Cancer TherapyJuly 9th, 2021
- Tool Helps Predicts Who Will Respond Best to Targeted Prostate Cancer TherapyJuly 8th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
